Harmony Biosciences Holdings, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
HRMY$33.55-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Income (Loss
| · · · · · · · · · | |||||||
|---|---|---|---|---|---|---|---|
| · · Year Ended December 31, | |||||||
| · · 2025 · · 2024 · · 2023 | |||||||
| Net product revenue | | $868,453 | | $714,734 | | $582,022 | |
| Cost of product sold | | 198,342 | | 156,815 | | 121,236 | |
| Gross profit | | 670,111 | | 557,919 | | 460,786 | |
| Operating expenses: | | | | | | | |
| Research and development (1) | | 189,594 | | 145,825 | | 76,063 | |
| Sales and marketing | | 119,512 | | 110,916 | | 97,404 | |
| General and administrative | | 152,536 | | 110,352 | | 95,289 | |
| Total operating expenses | | 461,642 | | 367,093 | | 268,756 | |
| Operating income | | 208,469 | | 190,826 | | 192,030 | |
| Loss on debt extinguishment | | — | | — | | (9,766) | |
| Other (expense) income, net | | (680) | | (68) | | 159 | |
| Interest expense | | | (14,649) | | (17,496) | | (23,757) |
| Interest income | | 21,924 | | 18,542 | | 14,730 | |
| Income before income taxes | | 215,064 | | 191,804 | | 173,396 | |
| Income tax expense | | (56,377) | | (46,311) | | (44,543) | |
| Net income | | $158,687 | | $145,493 | | $128,853 | |
| Unrealized income on investments | | 280 | | 64 | | 153 | |
| Comprehensive income | | $158,967 | | $145,557 | | $129,006 | |
| EARNINGS PER SHARE: | | | | | | | |
| Basic | | $2.76 | | $2.56 | | $2.17 | |
| Diluted | | $2.71 | | $2.51 | | $2.13 | |
| Weighted average number of shares of common stock - basic | | 57,492,277 | | 56,885,455 | | 59,469,648 | |
| Weighted average number of shares of common stock - diluted | | 58,544,570 | | 57,869,915 | | 60,372,397 | |
| (1) | Includes $15,000 in related party expenses for the year ended December 31, 2025, and no related party expenses for the years ended December 31, 2024, and 2023. |
- The accompanying notes are an integral part of the consolidated financial statements*
HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.